Ascendis Pharma As Stock EBITDA
| A1SN34 Stock | BRL 53.35 1.65 3.00% |
Ascendis Pharma AS fundamentals help investors to digest information that contributes to Ascendis Pharma's financial success or failures. It also enables traders to predict the movement of Ascendis Stock. The fundamental analysis module provides a way to measure Ascendis Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ascendis Pharma stock.
Ascendis |
Ascendis Pharma AS Company EBITDA Analysis
Ascendis Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Ascendis Pharma EBITDA | (364.64 M) |
Most of Ascendis Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascendis Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Ascendis Pharma AS reported earnings before interest,tax, depreciation and amortization of (364.64 Million). This is 141.56% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The ebitda for all Brazil stocks is 109.35% higher than that of the company.
Ascendis EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ascendis Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics of similar companies.Ascendis Pharma is currently under evaluation in ebitda category among its peers.
Ascendis Fundamentals
| Return On Equity | -0.67 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (15.89) % | |||
| Current Valuation | 34.82 B | |||
| Shares Outstanding | 57.03 M | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 1,080 X | |||
| Revenue | 7.78 M | |||
| Gross Profit | 4.25 M | |||
| EBITDA | (364.64 M) | |||
| Net Income | (383.58 M) | |||
| Book Value Per Share | 8.08 X | |||
| Cash Flow From Operations | (417.65 M) | |||
| Number Of Employees | 639 | |||
| Beta | 0.47 | |||
| Market Capitalization | 34.39 B | |||
| Total Asset | 1.08 B | |||
| Net Asset | 1.08 B |
About Ascendis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascendis Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Ascendis Stock
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.